Knight Therapeutics (GUD) M&A Announcement summary

Deal rationale and strategic fit

• Exclusive agreements to commercialize six products in Canada, including MYFEMBREE, ORGOVYX, vibegron, and three mature assets, effective June 4, 2025.

• Portfolio is highly synergistic with existing women's health and urology offerings, enhancing access for patients and providers.

• Transaction aligns with strategy to build a balanced portfolio of innovative and cash-generating assets, enhancing Canadian business scale.

• Acquisition capitalizes on international companies exiting Canada, providing growth opportunities.

• The transaction aligns with Sumitomo's strategy to focus on core U.S. brands and accelerate its oncology, regenerative medicine, and cell therapy pipeline.

Financial terms and conditions

• Total consideration: CAD 25.4 million upfront plus up to CAD 15.75 million in contingent milestone payments.

• Estimated CAD 7 million investment in inventory over eight months.

• Portfolio generated CAD 11.2 million in revenues in the 12 months ending March 31, 2025.

• Milestone payments are staggered and tied to sales targets, not a lump sum.

Synergies and expected cost savings

• Products highly complementary to current portfolio, leveraging existing sales and marketing infrastructure.

• Only four to six new hires expected across sales, medical, and marketing teams.

• Mature assets provide cash flow to fund investment in growth products.